KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Prepaid Assets (2016 - 2025)

Astrazeneca has reported Prepaid Assets over the past 11 years, most recently at $2.0 billion for Q4 2025.

  • Quarterly results put Prepaid Assets at $2.0 billion for Q4 2025, up 17.1% from a year ago — trailing twelve months through Dec 2025 was $2.0 billion (up 17.1% YoY), and the annual figure for FY2025 was $2.0 billion, up 17.1%.
  • Prepaid Assets for Q4 2025 was $2.0 billion at Astrazeneca, up from $1.7 billion in the prior quarter.
  • Over the last five years, Prepaid Assets for AZN hit a ceiling of $2.0 billion in Q4 2025 and a floor of $1.3 billion in Q4 2022.
  • Median Prepaid Assets over the past 5 years was $1.6 billion (2023), compared with a mean of $1.6 billion.
  • Biggest five-year swings in Prepaid Assets: dropped 12.85% in 2021 and later rose 21.67% in 2023.
  • Astrazeneca's Prepaid Assets stood at $1.5 billion in 2021, then dropped by 12.1% to $1.3 billion in 2022, then grew by 21.67% to $1.6 billion in 2023, then grew by 7.42% to $1.7 billion in 2024, then rose by 17.1% to $2.0 billion in 2025.
  • The last three reported values for Prepaid Assets were $2.0 billion (Q4 2025), $1.7 billion (Q4 2024), and $1.6 billion (Q4 2023) per Business Quant data.